European CHMP recommends approval of licence extension of avelumab (Bavencio)

The licence extension as monotherapy, is for first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.

Source:

European Medicines Agency